Department of Pharmacology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan.
Department of Pharmacology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan.
J Pharmacol Sci. 2020 Sep;144(1):23-29. doi: 10.1016/j.jphs.2020.06.007. Epub 2020 Jul 2.
Microglia maintain brain homeostasis as the main immune cells in the central nervous system. Activation of sigma-1 receptor (Sig1R) plays neuroprotective and anti-inflammatory roles in microglia. Recent studies showed that Sig1R expression level has been reduced in the brain of the patients with neurodegenerative diseases including Alzheimer's disease. However, the mechanisms underlying the down regulation of the Sig1R has not been clear. Treatment of rat primary cultured microglia with the inflammogen lipopolysaccharide (LPS) significantly decreased the expression of Sig1R mRNA in a concentration and time-dependent manner. The effects of LPS were blocked by pretreatment with TAK-242, a toll-like receptor 4 (TLR4) antagonist. Furthermore, inhibitors of transforming growth factor beta-activated kinase 1 (TAK1), p38 mitogen-activated protein kinase (MAPK) and histone deacetylase 6 (HDAC6) restored the LPS-induced downregulation of Sig1R. Thus, the current findings demonstrate that TLR4 activation leads to the downregulation of the Sig1R expression via TLR4-TAK1-p38 MAPK pathway and the inhibition of HDAC6 can increase Sig1R expression in microglia. The current findings suggest that downregulation of Sig1R may contribute to neuroinflammation-induced microglial dysfunction, regulation of microglial Sig1R may be novel therapeutic drug candidates for neurodegenerative and neuroinflammatory diseases.
小胶质细胞作为中枢神经系统中的主要免疫细胞,维持着大脑内环境的稳定。西格玛-1 受体(Sig1R)的激活在小胶质细胞中发挥着神经保护和抗炎作用。最近的研究表明,在包括阿尔茨海默病在内的神经退行性疾病患者的大脑中,Sig1R 的表达水平已经降低。然而,Sig1R 下调的机制尚不清楚。用炎症原脂多糖(LPS)处理大鼠原代培养的小胶质细胞,Sig1R mRNA 的表达呈浓度和时间依赖性显著降低。TLR4 拮抗剂 TAK-242 预处理可阻断 LPS 的作用。此外,转化生长因子β激活激酶 1(TAK1)、p38 丝裂原活化蛋白激酶(MAPK)和组蛋白去乙酰化酶 6(HDAC6)的抑制剂恢复了 LPS 诱导的 Sig1R 下调。因此,目前的研究结果表明,TLR4 激活通过 TLR4-TAK1-p38 MAPK 途径导致 Sig1R 表达下调,而抑制 HDAC6 可以增加小胶质细胞中 Sig1R 的表达。目前的研究结果表明,Sig1R 的下调可能导致神经炎症诱导的小胶质细胞功能障碍,调节小胶质细胞 Sig1R 可能成为神经退行性和神经炎症性疾病的新型治疗药物候选物。